In this study we investigated the efficacy and safety of icotinib plus sequential docetaxel (alone and in combination) against wild-type EGFR NSCLC in an animal model to determine whether this combination treatment may potentially benefit lung cancer patients in future. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.